Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is providing notice of an exchange of letters between FDA and the European Commission and the European Agency for the Evaluation of Medicinal Products (EMEA). The participants concluded this exchange of letters on September 12, 2003. These letters express the intentions of FDA, the European Commission, and EMEA to continue cooperative activities to further enhance and strengthen communication between the respective organizations and further enhance public health promotion and protection in the European Union and the United States of America.
The agreement became effective September 12, 2003.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Michelle Limoli, European Commission Office of International Programs (HFG-1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-0908.End Further Info End Preamble Start Supplemental Information
In accordance with 21 CFR 20.108(c), which states that all written agreements and memoranda of understanding between FDA and others shall be published in the Federal Register, the agency is publishing notice of this exchange of letters.Start Signature
Dated: December 18, 2003.
Assistant Commissioner for Policy.
BILLING CODE 4160-01-S
[FR Doc. 03-32005 Filed 12-30-03; 8:45 am]
BILLING CODE 4160-01-C